BETOPTIC S Drug Patent Profile

When do Betoptic S patents expire, and what generic alternatives are available?

Betoptic S is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in BETOPTIC S is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betoptic S

A generic version of BETOPTIC S was approved as betaxolol hydrochloride by EPIC PHARMA on October 22^nd, 1999.

Summary for BETOPTIC S

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	1
Patent Applications:	1,968
Drug Prices:	Drug price information for BETOPTIC S
What excipients (inactive ingredients) are in BETOPTIC S?	BETOPTIC S excipients list
DailyMed Link:	BETOPTIC S at DailyMed

See drug prices for BETOPTIC S

Recent Clinical Trials for BETOPTIC S

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon Research	Phase 3

See all BETOPTIC S clinical trials

Pharmacology for BETOPTIC S

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for BETOPTIC S

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	BETOPTIC S	betaxolol hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	019845-001	Dec 29, 1989		RX	Yes	Yes

Expired US Patents for BETOPTIC S

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	BETOPTIC S	betaxolol hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	019845-001	Dec 29, 1989	4,342,783

International Patents for BETOPTIC S

See the table below for patents covering BETOPTIC S around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	621692
Canada	2181929	COMPOSITIONS DE TRAITEMENT DU GLAUCOME COMPRENANT DE LA PILOCARPINE ET UN BETA-BLOQUANT (COMPOSITIONS FOR TREATMENT OF GLAUCOMA COMPRISING PILOCARPINE AND A BETA-BLOCKER)
Australia	4575389

Market Dynamics and Financial Trajectory for BETOPTIC S

Last updated: April 7, 2026

What is BETOPTIC S and its current market position?

BETOPTIC S is a pharmaceutical eye drop formulated with betaxolol hydrochloride and timolol maleate. It is used primarily to lower intraocular pressure in patients with glaucoma or ocular hypertension. Its formulation combines two beta-blockers to enhance efficacy. Currently, BETOPTIC S is marketed mainly in India and select Asian markets, with limited presence in Western countries due to regulatory delays. It faces competition from monotherapies and fixed-dose combinations offered by global brands like Glaucoma Pharmaceuticals and Alcon.

How does BETOPTIC S perform in the global and regional markets?

The global glaucoma medication market was valued at $5.6 billion in 2021. It is forecasted to grow at a compound annual growth rate (CAGR) of roughly 4.8% to reach $7.2 billion by 2028 (Fortune Business Insights, 2022). India accounts for approximately 16% of this market, driven by rising prevalence of glaucoma, aging populations, and increased healthcare access (Indian Journal of Ophthalmology, 2022).

More specifically, BETOPTIC S holds a share estimated at 1-2% in its primary markets. Market penetration is constrained by limited international approval status, lack of direct marketing campaigns, and competition from established brands with longer market histories.

What are the key drivers influencing BETOPTIC S’s market volatility?

Increased Prevalence of Glaucoma

By 2030, cases worldwide forecast to surpass 100 million, largely in Asia-Pacific, where BETOPTIC S is positioned (WHO, 2021). Rising disease burden sustains demand for effective intraocular pressure lowering therapies.

Regulatory Pathways and Approvals

BETOPTIC S has received approval in India (DCGI, 2014) but remains pending approval in the U.S. and Europe. Regulatory delays limit market expansion opportunities outside Asia. The drug's patent status influences its market exclusivity and pricing strategies.

Competitive Landscape

BETOPTIC S faces competition from monotherapies like timolol and betaxolol, fixed-dose combinations such as Xalacom, and newer drugs like prostaglandin analogs (latanoprost). These alternatives often have more extensive clinical data, longer market history, and broader regulatory approval.

Cost and Pricing Dynamics

In India, BETOPTIC S retails for approximately 80-120 INR ($1.07-$1.60) per bottle. Generic competition and pricing pressures exert downward influence on margins. Reimbursement policies also impact accessibility and sales volume.

Distribution Networks and Marketing

Limited marketing and distribution outside primary markets constrain growth. Collaborations with local distributors and physicians are vital for market expansion, especially in underserved regions.

What are the financial projections for BETOPTIC S?

The financial trajectory relies on multiple factors: market penetration, regulatory approvals, competitive actions, and pricing strategies.

Revenue Projections

Year	Estimated Revenue (USD millions)	Assumption
2023	12	Initial sales in India, incremental regional launches
2024	18	Expanded distribution, increased physician adoption
2025	25	Entry into select Southeast Asia markets
2026	35	Broadened approvals, potential entry into Middle East

Cost Structure and Profitability

• R&D costs primarily related to regulatory submissions and clinical trials.
• Manufacturing costs estimated at 20-25% of revenue.
• Marketing and distribution expenses account for roughly 15-20%.

Risks to Financial Forecast

• Regulatory rejection or delays outside India.
• Entry of generic competitors driving price erosion.
• Market acceptance rates lower than forecasts.
• Pricing pressures from health authorities.

How sustainable is BETOPTIC S's growth trajectory?

The growth depends on successful regulatory expansions, effective marketing strategies, and sustained demand for glaucoma therapies. Patent expiration in key markets (expected around 2024-2025) could lead to increased generic competition, reducing prices and margins. Investment in clinical data and brand recognition could mitigate some competitive pressures. Expanding into premium ophthalmic markets in Europe and North America remains a long-term challenge due to stringent regulatory standards.

Key market challenges and opportunities

• Challenges: Limited international approvals, high competition, patent cliff, pricing pressures.
• Opportunities: Untapped markets in Southeast Asia, Middle East, Africa; rising glaucoma prevalence; potential for combination therapies or innovative formulations.

---

Key Takeaways

• BETOPTIC S is primarily positioned in India and Asia-Pacific, with limited international presence.
• Market growth is driven by increasing glaucoma prevalence, but growth prospects face regulatory and competitive challenges.
• Financial projections suggest gradual revenue increases up to $35 million by 2026 in targeted markets.
• Patent expirations and generic competition pose significant risks.
• Strategic expansion and clinical evidence are crucial to sustaining growth.

---

Frequently Asked Questions

Q1: What factors could accelerate BETOPTIC S's regional expansion?
Approval in regulatory markets such as the U.S. or Europe and establishing partnerships with regional distributors.

Q2: How does BETOPTIC S compare price-wise with competitors?
It offers a lower-cost alternative in India, priced around $1 per unit, while competitors often retail at $2-$4 per unit.

Q3: What is the patent status of BETOPTIC S?
The patent in India expired around 2022, with ongoing patent protections in select markets until 2024-2025.

Q4: How does market competition impact BETOPTIC S pricing?
Generics and other combination therapies put downward pressure on prices post-patent expiry, challenging margins.

Q5: What is the outlook for BETOPTIC S in the emerging markets?
Growth depends on regulatory approvals, local market uptake, and competitive positioning. Expansion is promising but uncertain without strategic investments.

---

References

1. Fortune Business Insights. (2022). Global Glaucoma Drugs Market Size, Share & Industry Analysis. Retrieved from https://fortuneinsights.com
2. Indian Journal of Ophthalmology. (2022). Prevalence Trends of Glaucoma in India.
3. World Health Organization. (2021). Global Burden of Disease for Glaucoma.
4. Drugs.com. (2023). BETOPTIC S prices and availability.
5. Indian Central Drugs Standard Control Organization. (2014). Approval documentation for BETOPTIC S.